Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
PHASE2
The primary objective of this study is to determine the optimum dose(s) of ...
Status
Completed
Location
1237.9.00152 Boehringer Ingelheim Investigational Site
Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers
PHASE1
Study to investigate safety and tolerability of single, inhaled doses (2.5 ...
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
PHASE4
This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.)...